San Diego Business Journal’s Post

GSK purchased Elsie Biotechnologies for around $50 million to expand its platform R&D capabilities into oligonucleotide therapeutics. Elsie, founded in 2021, has a discovery platform with an ultra-high throughput proprietary process for evaluating oligonucleotide chemical space. The collaboration has made great strides in drug development for chronic hepatitis B and steatotic liver disease. GSK plans to apply its expertise in artificial intelligence and machine learning to support the development of predictive models for future oligonucleotide design. GSK will retain the entire Elsie team and plans to grow it. Stay up-to-date on all GSK news by subscribing to sdbj.com. https://lnkd.in/gM9K9HWq

  • No alternative text description for this image
Lily Flood

Regional Sales Director - Western US at Chiesi Global Rare Disease

1w

Great news!

Like
Reply

To view or add a comment, sign in

Explore topics